MeiraGTx/$MGTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MeiraGTx

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Ticker

$MGTX
Sector
Primary listing

Employees

386

MeiraGTx Metrics

BasicAdvanced
$677M
-
-$2.03
1.30
-

What the Analysts think about MeiraGTx

Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.

Bulls say / Bears say

MeiraGTx formed a strategic partnership with Hologen AI, gaining $200 million upfront and commitments for up to $230 million more to speed up its Phase 3 AAV-GAD program for Parkinson’s disease.
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to MeiraGTx’s AAV-GAD program for Parkinson’s disease in May 2025, offering an accelerated review process and signaling strong clinical benefit.
RBC Capital Markets increased its price target for MGTX to $13.00 and kept an Outperform rating, reflecting confidence in MeiraGTx’s partnerships and late-stage pipeline progress.
MeiraGTx reported a first-quarter loss per share of $0.51, missing the Zacks consensus estimate of a $0.38 loss and highlighting ongoing profitability issues.
Cash and cash equivalents at MeiraGTx fell to $32.2 million as of June 30, 2025, fueling concerns about the company's cash runway given its high usage rate.
The company faces a $75 million debt maturity in August 2026, creating refinancing risk amid ongoing R&D expenses.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MeiraGTx Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MeiraGTx Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MGTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs